The present study addressed the impact of human papillomavirus (HPV), p14, and the product of the retinoblastoma gene (pRb) in vulvar carcinoma in relation to other clinicopathologic variables and prognosis. We immunohistochemically studied 217 primary tumors from patients with vulvar carcinoma for the expression of pRb and p14. By the use of in situ hybridization, the primary tumors and 7 lymp...

Dear Editor, In many regions of the world, a vaccination program against the Human Papilloma Virus (HPV), to prevent the cancer of the cervix uteri, has been implemented. This is due to a relatively high prevalence of Human Papilloma Virus, which is implicated in aetiology of cervical cancer. As estimated by Globocan, in 2008, per 100,000 women, in very high incidence regions as SubSaharan Afri...

Whether antibodies to human papillomavirus (HPV) capsids, elicited by natural infection, are protective is unknown. This question was addressed in a populationbased cohort of 7046 women in Costa Rica by examining the association between baseline seroreactivity to HPV-16, HPV-18, or HPV-31 virus-like particles and the risk of subsequent HPV infection at a follow-up visit 5–7 years after enrollme...

BACKGROUND In the present study we retrospectively evaluated the results of outpatients who had an HPV analysis, and present objective evidence for the administration of preventive inoculation in our area. MATERIAL AND METHODS We retrospectively reviewed 532 outpatients who visited a single center between 2012 and 2016 and had an HPV infection analysis. The criteria for inclusion of patients wi...

(Abstracted from Obstet Gynecol 2021;137(2):225–233) Racial-ethnic disparities in access and outcomes the context of women's reproductive health continue to be pervasive United States. Contraceptive use, sexually transmitted infection care, human papillomavirus vaccination among younger women aged 18 25 years, cancers, preterm deliveries, low-birth-weight neonates, as well maternal morbidity mo...

A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9-26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) vaccines in girls and women 16-26 years of age, showed that the 9vHPV vaccine was generally well t...

UNLABELLED Previous studies have shown that the cancer-causing high-risk human papillomavirus (HPV) E6 oncoproteins have PDZ binding potential, an activity which is important for their ability to support the viral life cycle and to cooperate in the induction of malignancy. However, PDZ interactions are not constitutive, and they can be negatively regulated by phosphorylation within the E6 PDZ b...